MA27632A1 - Traitement de maladies bacteriennes des organes respiratoires par application locale de fluoroquinolones - Google Patents

Traitement de maladies bacteriennes des organes respiratoires par application locale de fluoroquinolones

Info

Publication number
MA27632A1
MA27632A1 MA28491A MA28491A MA27632A1 MA 27632 A1 MA27632 A1 MA 27632A1 MA 28491 A MA28491 A MA 28491A MA 28491 A MA28491 A MA 28491A MA 27632 A1 MA27632 A1 MA 27632A1
Authority
MA
Morocco
Prior art keywords
treatment
respiratory organs
fluoroquinolones
bacterial diseases
local application
Prior art date
Application number
MA28491A
Other languages
English (en)
Inventor
Rainer Endermann
Harald Labischinski
Christoph Ladel
Uwe Petersen
Ben Newton
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32851853&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27632(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10305318A external-priority patent/DE10305318A1/de
Priority claimed from DE10305319A external-priority patent/DE10305319A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of MA27632A1 publication Critical patent/MA27632A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)

Abstract

Traitement des maladies bactériennes des organes respiratoires L'invention se rapporte à des compositions inhalables à base de dérivés de l'acide quinolonecarboxylique prévues pour la lutte locale contre les maladies des organes respiratoires, en particulier les maladies pulmonaires.
MA28491A 2003-02-10 2005-09-09 Traitement de maladies bacteriennes des organes respiratoires par application locale de fluoroquinolones MA27632A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10305318A DE10305318A1 (de) 2003-02-10 2003-02-10 Behandlung bakteriell verursachter Lungenkrankheiten
DE10305319A DE10305319A1 (de) 2003-02-10 2003-02-10 Behandlung bakteriell verursachter Lungenkrankheiten

Publications (1)

Publication Number Publication Date
MA27632A1 true MA27632A1 (fr) 2005-11-01

Family

ID=32851853

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28491A MA27632A1 (fr) 2003-02-10 2005-09-09 Traitement de maladies bacteriennes des organes respiratoires par application locale de fluoroquinolones

Country Status (27)

Country Link
US (2) US8034817B2 (fr)
EP (1) EP1594500B1 (fr)
JP (2) JP4828405B2 (fr)
KR (1) KR101173696B1 (fr)
AR (1) AR043117A1 (fr)
AT (1) ATE482706T1 (fr)
AU (1) AU2004210399B2 (fr)
BR (1) BRPI0407368A (fr)
CA (1) CA2515262C (fr)
CY (1) CY1110998T1 (fr)
DE (1) DE502004011696D1 (fr)
DK (1) DK1594500T3 (fr)
EC (1) ECSP055959A (fr)
HR (1) HRP20050786B1 (fr)
IL (1) IL170027A (fr)
MA (1) MA27632A1 (fr)
MX (1) MXPA05008407A (fr)
MY (1) MY144714A (fr)
NO (1) NO331524B1 (fr)
NZ (1) NZ541681A (fr)
PE (1) PE20050189A1 (fr)
PT (1) PT1594500E (fr)
RU (1) RU2373937C9 (fr)
SI (1) SI1594500T1 (fr)
TW (1) TWI347843B (fr)
UY (1) UY28179A1 (fr)
WO (1) WO2004069253A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ541681A (en) * 2003-02-10 2009-02-28 Bayer Healthcare Ag Treatment of bacterial diseases of the respiratory organs by locally applying ciprofloxacin and its salts
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
WO2006033713A2 (fr) * 2004-08-09 2006-03-30 Chiron Corporation Procedes destines a l'inhalation de ciprofloxacine
RU2007119721A (ru) 2004-10-29 2008-12-10 Президент Энд Феллоуз Оф Гарвард Колледж (Us) Частицы для лечения легочной инфекции
NZ563417A (en) * 2005-05-18 2012-01-12 Mpex Pharmaceuticals Inc Aerosolized fluoroquinolones and uses thereof
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
KR101621986B1 (ko) 2008-05-15 2016-05-17 노파르티스 아게 플루오로퀴놀론의 폐 전달
CA2739897C (fr) 2008-10-07 2017-10-03 Mpex Pharmaceuticals, Inc. Formulations a base de fluoroquinolone sous forme d'aerosol pour une pharmacocinetique amelioree
US8629139B2 (en) 2008-10-07 2014-01-14 Mpex Pharmaceuticals, Inc. Topical use of Levofloxacin for reducing lung inflammation
WO2010048341A1 (fr) 2008-10-22 2010-04-29 Inspire Pharmaceuticals, Inc. Méthode de traitement de la fibrose cystique
DK2473170T3 (da) 2009-09-04 2019-08-12 Horizon Orphan Llc Anvendelse af aerosoliseret levofloxacin til behandling af cystisk fibrose
US9393243B1 (en) 2015-07-14 2016-07-19 Nilesh Parikh Topical Ciprofloxacin compositions
WO2018074880A2 (fr) * 2016-10-20 2018-04-26 한국화학연구원 Composition pharmaceutique de prévention ou de traitement de la pneumonie, comprenant un dérivé de quinolin-4-one ou un sel pharmaceutiquement acceptable associé en tant que principe actif

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3033157A1 (de) 1980-09-03 1982-04-01 Bayer Ag, 5090 Leverkusen 7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-naphthyridin-3-carbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
US4670444B1 (en) * 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
DE3525335A1 (de) * 1985-07-16 1987-01-22 Bayer Ag Embonate von chinoloncarbonsaeuren und ihren derivaten
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
FR2655545B1 (fr) * 1989-12-11 1994-06-10 Rhone Poulenc Sante Nouvelle application therapeutique des derives des fluoroquinolones.
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
RU2063770C1 (ru) * 1992-05-22 1996-07-20 Николай Сергеевич Скрипников Способ лечения гнойно-воспалительных заболеваний легких
RU2070045C1 (ru) * 1993-01-15 1996-12-10 Вячеслав Михайлович Провоторов Способ лечения хронического гнойного эндобронхита
DE19633480A1 (de) * 1996-08-20 1998-02-26 Bayer Ag Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren
DE19812160C1 (de) * 1998-03-20 1999-07-08 Bayer Ag Formkörper aus wirkstoffhaltigen thermoplastischen Polyurethanen
WO2000015207A2 (fr) * 1998-09-15 2000-03-23 Naeja Pharmaceutical Inc. Therapie combinee pour le traitement des inflammations, utilisant un ou plusieurs inhibiteurs d'elastase et un ou plusieurs agents antibacteriens
MXPA02004193A (es) * 1999-10-29 2002-12-13 Inhale Therapeutic Syst Composiciones de polvo seco que tienen caracteristicas de dispersion mejoradas.
DE19962470A1 (de) 1999-12-22 2001-07-12 Schulz Hans Herrmann Verwendung von Chemotherapeutika
DE10031043A1 (de) * 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
WO2003075889A1 (fr) * 2002-03-05 2003-09-18 Transave, Inc. Systeme d'inhalation pour le traitement d'infections intracellulaires
GB2387781A (en) * 2002-04-25 2003-10-29 Nektar Therapeutics Uk Ltd Particulate materials
NZ541681A (en) * 2003-02-10 2009-02-28 Bayer Healthcare Ag Treatment of bacterial diseases of the respiratory organs by locally applying ciprofloxacin and its salts

Also Published As

Publication number Publication date
PT1594500E (pt) 2010-12-17
JP4828405B2 (ja) 2011-11-30
PE20050189A1 (es) 2005-05-22
NO331524B1 (no) 2012-01-23
JP2011173929A (ja) 2011-09-08
IL170027A (en) 2012-02-29
DE502004011696D1 (de) 2010-11-11
EP1594500B1 (fr) 2010-09-29
UY28179A1 (es) 2004-09-30
KR101173696B1 (ko) 2012-08-13
TW200503716A (en) 2005-02-01
CA2515262C (fr) 2013-09-03
BRPI0407368A (pt) 2006-02-14
HRP20050786A2 (en) 2006-10-31
TWI347843B (en) 2011-09-01
RU2373937C9 (ru) 2010-07-27
US8034817B2 (en) 2011-10-11
EP1594500A1 (fr) 2005-11-16
MXPA05008407A (es) 2005-10-05
CA2515262A1 (fr) 2004-08-19
RU2373937C2 (ru) 2009-11-27
AR043117A1 (es) 2005-07-20
MY144714A (en) 2011-10-31
US20120010215A1 (en) 2012-01-12
ATE482706T1 (de) 2010-10-15
NO20054180L (no) 2005-09-08
CY1110998T1 (el) 2015-06-11
RU2005128132A (ru) 2006-02-10
AU2004210399B2 (en) 2010-02-18
HRP20050786B1 (hr) 2015-01-02
ECSP055959A (es) 2006-01-16
KR20050098309A (ko) 2005-10-11
US20040254194A1 (en) 2004-12-16
NO20054180D0 (no) 2005-09-08
HK1089380A1 (zh) 2006-12-01
AU2004210399A1 (en) 2004-08-19
WO2004069253A1 (fr) 2004-08-19
SI1594500T1 (sl) 2011-02-28
JP2006517210A (ja) 2006-07-20
NZ541681A (en) 2009-02-28
DK1594500T3 (da) 2011-01-24

Similar Documents

Publication Publication Date Title
BR0317572A (pt) Benzoxazinas e seus derivados como inibidores de pi3ks
ATE381535T1 (de) Phenethanolaminderivate
MXPA05009304A (es) Derivados de indol utiles para el tratamiento de enfermedades.
NO20062983L (no) Sulfonamid-derivater for behandling av sykdommer
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
ATE453636T1 (de) Substituierte 2,3-dihydro-1h-isoindol-1-one derivate und anwendungsverfahren
TW200505862A (en) 2-amino-pyridine derivatives useful for the treatment of diseases
TW200716596A (en) Substituted amide derivatives and methods of use
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA30289B1 (fr) Dérivés d'amines
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
NO20063761L (no) Sulfonamidderivater for behandling av sykdommer
EA200601802A1 (ru) Производные морфолина
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
TW200505865A (en) Compounds useful for the treatment of diseases
CY1110998T1 (el) Θεραπεια βακτηριακων ασθενειων των αναπνευστικων οργανων με τοπικη εφαρμογη φθοροκινολονων
EA200601462A1 (ru) Соединения для лечения заболеваний
EA200601510A1 (ru) Производные фенилэтаноламина в качестве бета-2-агонистов
ATE399758T1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
EP1802297A4 (fr) Compositions et procedes de traitement de maladies causees par l'infection yersinia spp
TNSN06302A1 (en) Composes pour le traitement de maladies
NO20063875L (no) Forbindelser som anvendes for behandling av sykdommer
UA93878C2 (ru) Производная бензилпиперазина, ee применение при лечении разных расстройств и фармацевтическая композиция, которая ee содержит